SHARE

Hims & Hers misses first-quarter estimates amid GLP-1 transition

The telehealth company missed Q1 revenue estimates and posted a surprise loss due to its transition from compounded to branded GLP-1 drugs. Shares fell over 12% despite raised full-year revenue forecasts, with profitability expected by 2027.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.